Surgery, Gastroenterology and Oncology
Vol. 29, No. 4, Dec 2024
The Fagotti s Score to Predict the Possibility of Optimal Cytoreduction in Advanced Epithelial Ovarian Cancer
Slavena Georgieva, Yavor Kornovski, Stanislav Slavchev, Yonka Ivanova, Angel Yordanov, Stoyan Kostov
REVIEW, Dec 2024
Article DOI: 10.21614/sgo-721
Read article

Ovarian cancer is the most common cause of lethality among women with gynecological cancers. In Europe, it ranks fifth in frequency in women after malignancies of the mammary gland, colon, lung and uterine body. Generally, it is diagnosed at an advanced stage (III-IV) due to the non-specificity of symptoms in the early stage and the lack of effective screening methods. The majority of patients with advanced epithelial ovarian cancer are indicated either for neoadjuvant chemotherapy followed by optimal cytoreduction or optimal cyto-reduction followed by adjuvant chemotherapy. This ....[more]

Evaluation of Sentinel Lymph Node Biopsy in Papillary Carcinoma of Thyroid During Total Thyroidectomy
Ahmed Ezzat Abd El-Rahiem Mohamed, Wafi Fouad Salib, Hesham Omran, George Magdy Halim Khella
ORIGINAL PAPER, Dec 2024
Article DOI: 10.21614/sgo-722
Read article

Background: Lymph node metastases are very common in papillary thyroid carcinoma affecting the survival of patients. The appropriate management of cervical lymph nodes is very important. Therefore, this study evaluated the utility of sentinel lymph node biopsy (SLNB) using methylene blue in the central neck compartment. Objective: The aim of this study is to investigate the possibility of using the SLNB to predict micro metastasis in papillary carcinoma of thyroid to avoid the unnecessary central lymph node dissection.

Patients and Methods: This pro....[more]

Risk Factors and Morbidity Pattern of Patients with Peptic Ulcer Undergoing Endoscopic Examination
Rifqa Saad Abdulwahhab AlSalman, Mohamed Hesham Shawi Alshawi, Alaa Salman Dawood Alahmed, Omran Habib, Abbas Ali Mansour, Ahmed Salih Alshewered
ORIGINAL PAPER, Dec 2024
Article DOI: 10.21614/sgo-712
Read article

Background: the prevalence of peptic ulcer (PU) is declining in Western because of widespread use of Helicobacter pylori (H. pylori) eradication drugs, however, it still high in developing regions. The study aimed to explore certain aspects of cases with PU and to identify the predictors of PU related to risk factors.

Material and Methods: the study was conducted at the endoscopic unit at Al-Sadr Teaching Hospital. A cross-sectional study involving 152 cases who underwent endoscopic examination by specialist doctors. All patients were inte....[more]

Urine Neutrophil Gelatinase-Associated Lipocalin for Assessment of Acute Kidney Injury Following Liver Transplantation
Abdel-Naser Abdel-Atty Gadallah, Amr Ragab Shalaby, Hanan Mosaad Bedair, Asmaa Yehia Ahmed Hikal, Hany Abd Elaziz Abd Elbary
ORIGINAL PAPER, Dec 2024
Article DOI: 10.21614/sgo-715
Read article

Background: acute kidney injury (AKI) is a prevalent complication that occurs following liver transplantation (LT). Aim: to evaluate the value of urinary neutrophil gelatinase-associated lipocalin (UNGAL) in detecting AKI following LT.

Material and Methods: the present study adopted a randomized, prospective, double-

blinded design. The trial was carried out on 38 patients who underwent evaluation for AKI

following LT at Menoufia University’s National Liver Institute. The study took place between January 2023 and June....[more]

Therapeutic Impact of RAS Testing on Survival Outcomes in Moroccan Metastatic Colorectal Cancer Patients
Sofia Fathi, Oussama Aazzane, Selma Guedanoui, Nezha Tawfiq, Souha Sahraoui, Fadila Guessous, Mehdi Karkouri
ORIGINAL PAPER, Dec 2024
Article DOI: 10.21614/sgo-718
Read article

Introduction: RAS mutations, particularly KRAS and NRAS mutations, are frequent drivers of metastatic colorectal cancer (mCRC) and confer resistance to anti-EGFR targeted therapy. This study investigated the impact of RAS molecular testing on treatment patterns and survival outcomes in Moroccan mCRC patients.

Material and Methods: A retrospective study was conducted among patients diagnosed mCRC and treated at Ibn Rochd University Hospital, Casablanca, Morocco, between 2019 and 2023. All patients received first-line chemotherapy followed b....[more]

Survival Analysis of Patients with Primary Retroperitoneal Tumors in a Specialty Hospital in Quito-Ecuador in the Period 2009-2019
Andrés Moreno Roca, Xavier Sánchez, Ricardo Manosalvas, Luciana Armijos, Ruth JimboSotomayor, Oscar Jaramillo, Alfredo Viloria
ORIGINAL PAPER, Dec 2024
Article DOI: 10.21614/sgo-701
Read article

Purpose: Primary retroperitoneal tumors (PRT) are various heterogeneous types of

neoplasms that have a frequency of less than 1%. The main factors associated with survival are time with the disease, treatment received, and recurrence. This study analyzed the clinical and pathological factors that influence the survival outcomes in patients with PRT.

Material and Methods: A retrospective cohort study and a survival analysis were conducted using the available data in the electronic clinical records of patients with a diagnosis of PRT....[more]

Pemphigus in a Patient Treated with Immune Checkpoint Inhibitor for Advanced Cutaneous Squamous Cell Carcinoma
Katia Lanzafame, Maria Carmela Careri, Vitalinda Pumo, Gabriella Buccafusca, Salvatore Lo Bianco, Paolo Tralongo
CASE REPORT, Dec 2024
Article DOI: 10.21614/sgo-598
Read article

Cutaneous squamous cell carcinoma is the second most common skin cancer. Cemiplimab, an antiPD-1 monoclonal antibody, is the first immunotherapy approved for patients with locally advanced cSCC. Phase I and II studies showing high antitumor activity and good tolerability of cemiplimab. However, very little data is available on cemiplimab in real life and in frail, elderly and immunocompromised patients. We report the case of an elderly patient (84 years old) affected by metastatic cSCC. The patient performed 16 cycles of treatment with cemiplimab with complete pathological respons....[more]

Primary Hepatic Neuroendocrine Tumor Managed with Major Liver Resection: A Case Report
Mai M. Rizk, Ahmed Farouk, Rehab T. Eldesoky, Ahmed Shehta
CASE REPORT, Dec 2024
Article DOI: 10.21614/sgo-711
Read article

Background: Primary hepatic neuroendocrine tumors (PHNETs) are very rare tumors. The diagnosis and management of PHNET remains an unusual and challenging issue.

Case Presentation: A 22-year-old woman, presented with recurrent dull aching right hypochondrial pain. She underwent detailed abdominal radiological evaluation revealing a well-defined mass lesion in the right hemi-liver measuring about 12 x 8 cm with vague

radiologic features. Upper and lower gastro-intestinal endoscopes were free. Upon exploration, there was a large mass ....[more]


Watch Video Articles


For Authors



Journal Subscriptions

Current Issue

Jun 2025

Supplements

Instructions for authors
Online submission
Contact
ISSN: 2559 - 723X (print)

e-ISSN: 2601 - 1700 (online)

ISSN-L: 2559 - 723X

Journal Abbreviation: Surg. Gastroenterol. Oncol.

Surgery, Gastroenterology and Oncology (SGO) is indexed in:
  • SCOPUS
  • EBSCO
  • DOI/Crossref
  • Google Scholar
  • SCImago
  • Harvard Library
  • Open Academic Journals Index (OAJI)

Open Access Statement

Surgery, Gastroenterology and Oncology (SGO) is an open-access, peer-reviewed online journal published by Celsius Publishing House. The journal allows readers to read, download, copy, distribute, print, search, or link to the full text of its articles.

Journal Metrics

Time to first editorial decision: 25 days
Rejection rate: 61%
CiteScore: 0.2



Meetings and Courses in 2025
Meetings and Courses in 2024
Meetings and Courses in 2023
Meetings and Courses in 2022
Meetings and Courses in 2021
Meetings and Courses in 2020
Meetings and Courses in 2019
Verona expert meeting 2019

Creative Commons License
Surgery, Gastroenterology and Oncology applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits readers to copy and redistribute the material in any medium or format, remix, adapt, build upon the published works non-commercially, and license the derivative works on different terms, provided the original material is properly cited and the use is non-commercial. Please see: https://creativecommons.org/licenses/by-nc/4.0/
Publisher’s Note:
The opinions, statements, and data contained in article are solely those of the authors and not of Surgery, Gastroenterology and Oncology journal or the editors. Publisher and the editors disclaim responsibility for any damage resulting from any ideas, instructions, methods, or products referred to in the content.